Not provided
Not provided
Not provided
Not provided
Not provided
Business decision
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of the study is to characterize the safety profile and duration of bronchodilation of a single dose of inhaled TV48108.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TV48108 - Healthy Volunteers | Experimental | Stage 1 is a randomized, placebo-controlled, double-blind, single-dose study. Healthy subjects will be randomized to receive a single inhaled dose of TV48108 120 µg |
|
| Placebo - Healthy Volunteers | Placebo Comparator | Placebo |
|
| TV48108 15 µg COPD | Experimental | Stage 2 consists of a 2-period open-label study with an ipratropium bromide reference to evaluate the single administration of 3 ascending doses of inhaled TV48108 in COPD patients. |
|
| TV48108 60 µg COPD | Experimental | Stage 2 |
|
| TV48108 120 µg COPD | Experimental | Stage 2 . |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| TV48108 | Drug | TV48108 15, 60, 120 μg |
|
| Measure | Description | Time Frame |
|---|---|---|
| Baseline adjusted forced expiratory volume in 1 second area under the curve over 12 hours (FEV1 AUC0-12h). | Day 1 (pre-dose, up to 12 hours post-dose) |
| Measure | Description | Time Frame |
|---|---|---|
| Baseline Adjusted Trough 12 hour forced expiratory volume in 1 second (FEV1) | Day 1 (pre-dose, up to 12 hours post-dose) | |
| Percentage of Participants with Adverse Events | 28 Days |
Not provided
Inclusion Criteria:
Stage 1 (Healthy Volunteers)
Stage 2 (Chronic Obstructive Lung Disease (COPD) patients)
Exclusion Criteria:
Stage 1 (Healthy Volunteers)
Stage 2 (Chronic Obstructive Lung Disease (COPD) patients)
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Teva Medical Expert, MD | Teva Branded Pharmaceutical Products R&D, Inc. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Teva Investigational Site 13038 | Medford | Oregon | United States | |||
| Teva Investigational Site 13039 |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Placebo | Drug | Placebo Comparator |
|
|
| Spartanburg |
| South Carolina |
| United States |
| Teva Investigational Site 78992 | Clayton | Australia |
| Teva Investigational Site 78993 | Daws Park | Australia |
| Teva Investigational Site 78991 | Melbourne | Australia |
| Teva Investigational Site 79041 | Auckland | New Zealand |
| Teva Investigational Site 79040 | Christchurch | New Zealand |
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided